



Universiteit  
Leiden  
The Netherlands

## Deep vein thrombosis : diagnostic and prognostic challenges

Dronkers, C.E.A.

### Citation

Dronkers, C. E. A. (2019, January 8). *Deep vein thrombosis : diagnostic and prognostic challenges*. Retrieved from <https://hdl.handle.net/1887/68270>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/68270>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/68270> holds various files of this Leiden University dissertation.

**Author:** Dronkers, C.E.A.

**Title:** Deep vein thrombosis : diagnostic and prognostic challenges


**Issue Date:** 2019-01-08

Disease prevalence dependent  
failure rate in diagnostic  
management studies in  
suspected deep vein  
thrombosis: communication  
from the SSC of the ISTH

3

C.E.A. Dronkers, Y.M. Ende-Verhaar, P.A. Kyrle,  
M. Righini, S.C. Cannegieter, M.V. Huisman, F. A.  
Klok FOR THE SUBCOMMITTEE ON PREDICTIVE  
AND DIAGNOSTIC VARIABLES IN THROMBOTIC  
DISEASE

*Journal of Thrombosis and Haemostasis* 2017; 15:2270-3





## INTRODUCTION

Objective diagnosis of deep vein thrombosis (DVT) is important, because untreated DVT is associated with a high risk of acute pulmonary embolism and post-thrombotic syndrome. As it is impossible to diagnose DVT on the basis of clinical symptoms or laboratory tests alone, objective imaging testing is needed to confirm or refute the diagnosis. The favoured strategy for the diagnostic management of suspected first DVT is the combination of pre-test probability assessment, D-dimer testing and (serial) compression ultrasound (CUS).<sup>1</sup> Recently, several new diagnostic tests have been suggested, such as a higher D-dimer threshold of  $<1.0 \mu\text{g/ml}$  if there is a low clinical probability, computed tomography-venography if it is impossible to perform CUS, and magnetic resonance direct thrombus imaging (MRDTI) for the diagnosis of ipsilateral recurrent DVT.<sup>2</sup>

Notably, because contrast venography is still the reference for diagnosing DVT, current guidelines state that the standard against which all DVT diagnostic management studies should be evaluated is the percentage of patients with a venous thromboembolism (VTE) during 3 months of follow-up despite a normal venography finding, to ensure that new diagnostic tests or algorithms are tested against the reference standard.<sup>1</sup> This failure rate has been shown to be 1.3% (upper limit 95% confidence interval [CI] 4.4%) in a study evaluating 160 consecutive patients with suspected acute DVT and a negative venography finding.<sup>3</sup> Importantly, the threshold for doctors to suspect DVT and initiate diagnostic testing has lowered over the past few years. This trend is probably attributable to better awareness of the disease, and the availability of non-invasive CUS as an alternative to venography. This trend has been shown for suspected PE as well.<sup>4</sup> This lower diagnostic threshold has led to a sharp decrease in DVT prevalence in examined patients in recent studies, to even below 10%.<sup>5</sup> Bayes' theorem states that disease prevalence (the pre-test probability of having the disease) and failure rate (the post-test probability of having the disease) are related. This implies that, because the disease prevalence has decreased over the past few years, the diagnostic standard of diagnostic management studies should be changed accordingly.<sup>6</sup> In analogy to the SSC communication entitled: 'Towards a tailored diagnostic standard for future diagnostic studies in pulmonary embolism: communication from the SSC of the ISTH',<sup>4</sup> the purpose of this ISTH SSC communication was to evaluate the association of DVT prevalence and diagnostic failure rate in published studies on diagnosis of DVT, in order to propose a new diagnostic safety threshold for future studies on the diagnostic management of suspected DVT.

## METHODS


This systematic review and meta-analysis was performed in accordance with the PRISMA criteria.<sup>7</sup> All parts of the systematic review were performed by two independent reviewers (C.D. and Y.E.), disagreements were resolved by an additional reviewer (F.K.). A literature search of Pubmed, Embase, Web of Science, Cochrane and Cohchrane central register of controlled trials (central) was performed on 29 February 2016 with the aim to find all high-quality diagnostic studies in acute DVT from 1990 on. First, all references were screened by title and abstract. After exclusion of non-relevant studies, full-text articles were analysed for eligibility before final study selection. Study selection criteria were: 1) prospective study design, 2) pre-specified study protocol, 3) clear description of inclusion and exclusion criteria, 4) inclusion of >100 consecutive patients, 5) at least 3 months of follow-up, 6) <5% lost to follow-up, and 7) use of an appropriate diagnostic standard. The last of these was defined as: (an algorithm consisting of) a validated clinical decision rule combined with a highly sensitive D-dimer test, venography, and whole leg CUS or serial proximal CUS. In both CUS strategies, the lack of compressibility of a venous segment under the ultrasound probe was diagnostic for DVT. In case of suspected recurrent DVT, a non-compressible previously normalized vein or the enlargement of a residual thrombus diameter of  $\geq 2$  mm as compared with the previous CUS assessment was diagnostic for recurrent DVT.<sup>8</sup> To avoid risk of bias, only studies meeting all criteria were included in this meta-analysis. From each selected study, the following information was extracted: 1) year of publication, 2) total number of included patients, 3) diagnostic test or algorithm, 4) focus on proximal DVT only or also distal DVT 5) DVT prevalence at baseline and 6) failure rate defined by the incidence of patients with VTE despite a negative test during 3-month follow-up. Two graphs were plotted: one with year of publication versus DVT prevalence, the second with DVT prevalence versus failure rate. Reference lines with 95% confidence intervals, adjusted for number of patients included in the studies were calculated by the use of least squares linear regression analysis. The formula of this reference line was predefined as being the most accurate safety threshold for future studies. Primary analysis was based on studies with a 3-month follow-up period. A sensitivity analysis was performed that included studies with longer follow-up periods and studies restricted to proximal DVT. Statistical analyses were performed using SPSS version 23 (IBM, Armonk, NY, USA) and Stata 14.0 (Stata Corp., college Station, TX, USA).

## FINDINGS


After the literature search, 1034 potentially relevant studies were identified and screened for eligibility. Seven hundred and nineteen studies were excluded after title and abstract screening, leaving 315 studies for full text evaluation. Finally, 51 studies were included, of which 46 had a follow-up period of exactly 3 months and were selected for the primary analysis. Study selection flowchart and reasons for exclusion are shown in **Appendix I**. Study characteristics and extracted information is summarized in **Appendix II**. The selected studies included a total of 28,145 patients, with a mean baseline DVT prevalence of 20% (95%CI 19.9-20.1, range 5.7-47%) and a failure rate of 0.80% (95%CI 0.79-0.81, range 0-2.8%). The reference line of the graph plotting DVT prevalence versus year of publication showed a decrease in DVT prevalence over the years, with a 2.65% decrease per 5 years, according to the formula:  $Y=27.95-0.53*x$  ( $R^2$  0.066,  $p<0.001$ ; **Fig.1a**). The second graph demonstrates that the mean failure rate increased with higher disease prevalence in individual studies with an absolute 1.0% higher DVT prevalence leading to a mean 0.026 percentage points increase in failure rate per 1% increase in prevalence, according to the formula  $0.28 + 0.026*x$  ( $R^2$  0.195,  $p<0.001$ ; **Fig.1b**). The number 0.28 in this formula indicates the 3-month VTE incidence in a virtual, extrapolated study with 0% DVT prevalence at baseline (which is the cross-point of the reference line with the y-axis). The upper limit of the 95% CI of this regression line resulted in the formula:  $1.25 + 0.026*x$ . The sensitivity analysis, including five additional studies with follow-up beyond the first 3 months and the one limited to studies analysing proximal DVT only, indicated comparable study outcomes (formulas  $0.45 + 0.02*x$  and  $0.46+0.02*x$  respectively).

## RECOMMENDATIONS

A DVT prevalence-dependent, diagnostic safety threshold should be considered for future diagnostic studies. Our systematic review and meta-analysis of high-quality DVT diagnostic management studies shows that the failure rate increases with 0.03 points per percentage point higher disease prevalence. We suggest that the formula with this regression coefficient of 0.03 combined with a baseline DVT prevalence of 1.25% should be used as diagnostic standard, based on the upper limit of the 95% confidence interval of our pooled analysis. We suggest that all future studies incorporate this formula in their power-analysis to prevent new diagnostic tests being evaluated in underpowered studies that do not allow for sufficient validation. For a power calculation example, we refer to our previous SSC communication.<sup>4</sup>



**Figure 1a.** Decrease of disease prevalence over the last years



**Figure 1b.** Prevalence versus failure rate in high quality deep vein thrombosis diagnostic management studies. Grey area depicts the 95% confidence interval of the reference line.

## DISCUSSION


This study confirms the decreasing baseline disease prevalence of DVT diagnostic management studies over the last years. We suggest incorporation of the DVT prevalence-dependent diagnostic safety threshold in all future diagnostic studies. The formula is, for example, also applicable to studies including patients with a higher a-priori risk of VTE, such as patients with cancer or previous VTE, mainly due to the fact that these patients



were well represented in the studies included in the meta-analysis and the adaptation of the accepted failure rate to this higher a-priori risk. Of note, the proposed diagnostic safety threshold in this study is not meant to be used in clinical practice, but merely as guidance for planning of future diagnostic studies. Notably, when using diagnostic tests in clinical practice, it is important to keep in mind that the diagnostic indices of tests may differ in specific patient groups. It was, for instance, shown that both sensitivity and specificity of the Wells rule variables differ in patients with cancer, which can lead to a higher rate of false negative test results in such patients.<sup>9</sup> Ideally, this phenomenon should be acknowledged in the design and reporting of (future) diagnostic studies by investigating diagnostic accuracy across different subgroups, where appropriate. Besides a proper safety threshold, it is also important to take the lower costs and/or lower risk of potential harms of a new test into account before its implementation. Even so, a relevant loss of sensitivity of a new diagnostic test does not easily weigh up against potential economic benefits. In conclusion, we propose a new diagnostic safety threshold for future DVT diagnostic management studies, in which the threshold is adjusted for the expected disease prevalence of the study population.

## REFERENCES

1. Bates SM, Jaeschke R, Stevens SM, et al. Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141:e351S-418S.
2. Dronkers CE, Klok FA, Huisman MV. Current and future perspectives in imaging of venous thromboembolism. *Journal of thrombosis and haemostasis : JTH* 2016;14:1696-710.
3. Hull R, Hirsh J, Sackett DL, et al. Clinical validity of a negative venogram in patients with clinically suspected venous thrombosis. *Circulation* 1981;64:622-5.
4. Dronkers CEA, van der Hulle T, Le Gal G, et al. Towards a tailored diagnostic standard for future diagnostic studies in pulmonary embolism: communication from the SSC of the ISTH. *Journal of thrombosis and haemostasis : JTH* 2017;15:1040-3.
5. Linkins LA, Bates SM, Lang E, et al. Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial. *Annals of internal medicine* 2013;158:93-100.
6. Bayes T. An Essay Toward Solving a Problem in the Doctrine of Chances. *Philosophical Transactions of the Royal Society of London* 1764;53:370-418.
7. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Annals of internal medicine* 2009;151:264-9, w64.
8. Prandoni P, Lensing AW, Bernardi E, Villalta S, Bagatella P, Girolami A. The diagnostic value of compression ultrasonography in patients with suspected recurrent deep vein thrombosis. *Thrombosis and haemostasis* 2002;88:402-6.
9. Lucassen W, Geersing GJ, Erkens PM, et al. Clinical decision rules for excluding pulmonary embolism: a meta-analysis. *Annals of internal medicine* 2011;155:448-60.



**Appendix I.** Flowchart of study selection

**Appendix II.**

<b>Author</b>	<b>Year of publication</b>	<b>Diagnostic tests/ algorithm</b>	<b>Only proximal thrombosis</b>	<b>Follow-up (months)</b>	<b>Number of patients</b>	<b>Disease prevalence at baseline (%)</b>	<b>Failure rate (%)</b>
Aguilar <sup>1</sup>	2007	Wells rule, D-dimer, (serial) proximal CUS	yes	3	105	44.8	1.7
Anderson <sup>2</sup>	1999	CDR, (serial) proximal CUS, venography	no	3	344	13.1	0.7
Anderson <sup>3</sup>	2003	CDR, (serial) proximal CUS, venography	no	3	1109	17.9	0.79
Bates <sup>4</sup>	2003	Wells rule, D-dimer, (serial) proximal CUS	yes	3	556	8.9	1.2
Bernardi <sup>5</sup>	1998	CUS, D-dimer test=> positive: serial proximal CUS	yes	3	946	28	0.4
Bernardi <sup>6</sup>	2008	Randomisation between D-dimer + serial proximal CUS and whole leg CUS	no	3	2098 (1045/1053)	22.1/26.4	0.9/1.2
Birdwell <sup>7</sup>	1998	(Serial) proximal CUS + venography to confirm DVT	no	3	405	17	0.6
Birdwell <sup>8</sup>	2000	(Serial) proximal CUS + venography to confirm DVT	no	3	709	15	0.7
Büller <sup>9</sup>	2009	CDR, D-dimer, US	yes	3	1002	13	1.25
Chan <sup>10</sup>	2007	(Serial) CUS	no	3	149	8	0.73
Chan <sup>11</sup>	2010	(Serial) CUS	no	3	249	6.8	0
Chan <sup>12</sup>	2013	(Serial) CUS	no	3	221	7.2	0.49
Cini <sup>13</sup>	2014	Wells rule, D-dimer, (Serial) proximal CUS	yes	3	326	16.6	0
Cogo <sup>14</sup>	1998	(Serial) CUS	no	6	1702	24	0.7
Cornuz <sup>15</sup>	2002	Wells rule, D-dimer,	no	3	278	29	1.0
Elias <sup>16</sup>	2003	Whole leg CUS	no	3	623	32.8	0.5
Engelberger <sup>17</sup>	2011	Wells rule, D-dimer, whole leg CUS	no	3	298	27	0.5
Gibson <sup>18</sup>	2009	Wells rule, D-dimer, serial proximal CUS/ whole leg CUS	no	3	1002	15.8	0.95
Heijboer <sup>19</sup>	1993	(Serial) CUS + venography to confirm DVT	no	6	490	19	1.5
Hogg <sup>20</sup>	2012	Wells rule, D-dimer (serial) CUS	no	3	199	20.6	0
Imbert <sup>21</sup>	2006	Wells rule, D-dimer (serial) proximal CUS	yes	3	534	19.2	0.7

**Appendix II.** (continued)

<b>Author</b>	<b>Year of publication</b>	<b>Diagnostic tests/ algorithm</b>	<b>Only proximal thrombosis</b>	<b>Follow-up (months)</b>	<b>Number of patients</b>	<b>Disease prevalence at baseline (%)</b>	<b>Failure rate (%)</b>
Janes <sup>22</sup>	2001	Wells rule, D-dimer, US	no	3	431	21.6	0.3
Kahn <sup>23</sup>	2001	Contrast venography	no	6	159	32	0.9
Kearon <sup>24</sup>	2001	Wells rule, D-dimer, serial US/impedence plethysmography + venography	no	3	445	14	0.26
Kearon <sup>25</sup>	2005	Randomisation between D-dimer +venography/serial CUS	no	6	408/402	4.7/1.2	2.1/0.75
Kraaijenhagen <sup>26</sup>	2002	CDR, D-dimer, (serial) CUS	no	3	1756	23	1.3
Le Gal <sup>27</sup>	2012	Whole leg CUS	no	3	210	10.5	4
Legnani <sup>28</sup>	2010	Wells rule, D-dimer, serial US	no	3	401	22.4	0
Linkins <sup>29</sup>	2013	Wells rule, Randomisation between testing D-dimer in all patients/ selective testing dependent on Wells rule, CUS	yes	3	863/860	6.5/5.7	0.5/0.5
Noren <sup>30</sup>	2002	Duplex US, venography is patients with equivocal US results	no	3	580	24	0.29
Penaloza <sup>31</sup>	2006	Wells rule, D-dimer, (serial) proximal CUS	yes	3	214	18	1.1
Perrier <sup>32</sup>	1999	Wells rule, D-dimer, CUS, venography	no	3	474	33.5	2.6
Prandoni <sup>33</sup>	2002	(serial)CUS + venography for all patients with positive CUS	yes	6	205	27	1.3
Prandoni <sup>34</sup>	2007	Proximal CUS, serial CUS when D-dimer positive	yes	3	146	30	0
Robinson <sup>35</sup>	2002	D-dimer + CUS	no	3	437	30	0.65
Ruiz-Gimenez <sup>36</sup>	2004	Wells rule, d-dimer (serial) proximal CUS	yes	3	401	25	0.99
Schellong <sup>37</sup>	2003	Whole leg CUS	no	3	1646	12	0.3
Schouten <sup>38</sup>	2015	Oudega rule, d-dimer, CUS	no	3	348	47	2.2

**Appendix II.** (continued)

<b>Author</b>	<b>Year of publication</b>	<b>Diagnostic tests/ algorithm</b>	<b>Only proximal thrombosis</b>	<b>Follow-up (months)</b>	<b>Number of patients</b>	<b>Disease prevalence at baseline (%)</b>	<b>Failure rate (%)</b>
Schutgens <sup>39</sup>	2003	Wells rule, D-dimer, CUS, serial CUS when D-dimer positive	yes	3	812	38	1.6
Siragusa <sup>40</sup>	2004	Wells rule, D-dimer, serial US	no	3	409	22.2	0.63
Sluzewski <sup>41</sup>	1991	(serial) proximal CUS	yes	3	174	38	2.8
Stevens <sup>42</sup>	2004	CUS	no	3	445	13.7	0.8
Stevens <sup>43</sup>	2013	Wells rule, whole leg CUS	no	3	183	8.7	0.6
Subramaniam <sup>44</sup>	2005	Whole leg CUS	no	3	526	21.5	0.24
Subramaniam <sup>45</sup>	2006	Whole leg CUS	no	3	453	19.2	0
ten Wolde <sup>46</sup>	2002	D-dimer+ (serial) CUS	no	3	1739	23	1.3
Tick <sup>47</sup>	2002	Wells rule, D-dimer, single CUS/(serial)CUS	no	3	811	42	1.5
van der Hulle <sup>48</sup>	2013	Wells rule, D-dimer, (serial) CUS	yes	3	389	22	0
Wells <sup>49</sup>	1997	Wells rule, (serial) CUS, venography	yes	3	593	15.5	0.6
Wells <sup>50</sup>	1999	Wells rule, (serial) CUS	yes	3	150	27	1.8
Wells <sup>51</sup>	2003	Wells rule, unlikely probability group: randomisation between first US or D-dimer	yes	3	566/530	15/14.5	0.4/1.3

1. Aguilar C, del Villar V. Combined D-dimer and clinical probability are useful for exclusion of recurrent deep venous thrombosis. *American journal of hematology* 2007;82:41-4.
2. Anderson DR, Wells PS, Stiell I, et al. Thrombosis in the emergency department: Use of a clinical diagnosis model to safely avoid the need for urgent radiological investigation. *Archives of internal medicine* 1999;159:477-82.
3. Anderson DR, Kovacs MJ, Kovacs G, et al. Combined use of clinical assessment and d-dimer to improve the management of patients presenting to the emergency department with suspected deep vein thrombosis (the EDITED Study). *Journal of thrombosis and haemostasis : JTH* 2003;1:645-51.
4. Bates SM, Kearon C, Crowther M, et al. A diagnostic strategy involving a quantitative latex D-dimer assay reliably excludes deep venous thrombosis. *Annals of internal medicine* 2003;138:787-94.
5. Bernardi E, Prandoni P, Lensing AW, et al. D-dimer testing as an adjunct to ultrasonography in patients with clinically suspected deep vein thrombosis: prospective cohort study. The Multicentre Italian D-dimer Ultrasound Study Investigators Group. *BMJ (Clinical research ed)* 1998;317:1037-40.
6. Bernardi E, Camporese G, Buller HR, et al. Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis: a randomized controlled trial. *Jama* 2008;300:1653-9.
7. Birdwell BG, Raskob GE, Whitsett TL, et al. The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. *Annals of internal medicine* 1998;128:1-7.
8. Birdwell BG, Raskob GE, Whitsett TL, et al. Predictive value of compression ultrasonography for deep vein thrombosis in symptomatic outpatients: clinical implications of the site of vein non-compressibility. *Archives of internal medicine* 2000;160:309-13.
9. Buller HR, Ten Cate-Hoek AJ, Hoes AW, et al. Safely ruling out deep venous thrombosis in primary care. *Annals of internal medicine* 2009;150:229-35.
10. Chan WS, Chunilal S, Lee A, Crowther M, Rodger M, Ginsberg JS. A red blood cell agglutination D-dimer test to exclude deep venous thrombosis in pregnancy. *Annals of internal medicine* 2007;147:165-70.
11. Chan WS, Lee A, Spencer FA, et al. D-dimer testing in pregnant patients: towards determining the next 'level' in the diagnosis of deep vein thrombosis. *Journal of thrombosis and haemostasis : JTH* 2010;8:1004-11.
12. Chan WS, Spencer FA, Lee AY, et al. Safety of withholding anticoagulation in pregnant women with suspected deep vein thrombosis following negative serial compression ultrasound and iliac vein imaging. *CMAJ* 2013;185:E194-E200.
13. Cini M, Legnani C, Frascaro M, Sartori M, Cosmi B, Palareti G. D-dimer use for deep venous thrombosis exclusion in elderly patients: a comparative analysis of three different approaches to establish cut-off values for an assay with results expressed in D-dimer units. *Int J Lab Hematol* 2014;36:541-7.
14. Cogo A, Lensing AW, Koopman MM, et al. Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. *BMJ (Clinical research ed)* 1998;316:17-20.
15. Cornuz J, Ghali WA, Hayoz D, Stoianov R, Depairon M, Yersin B. Clinical prediction of deep venous thrombosis using two risk assessment methods in combination with rapid quantitative D-dimer testing. *Am J Med* 2002;112:198-203.

16. Elias A, Mallard L, Elias M, et al. A single complete ultrasound investigation of the venous network for the diagnostic management of patients with a clinically suspected first episode of deep venous thrombosis of the lower limbs. *Thrombosis and haemostasis* 2003;89:221-7.
17. Engelberger RP, Aujesky D, Calanca L, Staeger P, Hugli O, Mazzolai L. Comparison of the diagnostic performance of the original and modified Wells score in inpatients and outpatients with suspected deep vein thrombosis. *Thromb Res* 2011;127:535-9.
18. Gibson NS, Schellong SM, Kheir DY, et al. Safety and sensitivity of two ultrasound strategies in patients with clinically suspected deep venous thrombosis: a prospective management study. *Journal of thrombosis and haemostasis : JTH* 2009;7:2035-41.
19. Heijboer H, Buller HR, Lensing AW, Turpie AG, Colly LP, ten Cate JW. A comparison of real-time compression ultrasonography with impedance plethysmography for the diagnosis of deep-vein thrombosis in symptomatic outpatients. *N Engl J Med* 1993;329:1365-9.
20. Hogg K, Hinchliffe E, Halsam S, Valkov A, Lecky F. Is ischaemia-modified albumin a test for venous thromboembolism? *Emergency Medicine Journal* 2012;29:455-9.
21. Imberti D, Ageno W, Dentali F, Giorgi PM, Croci E, Garcia D. Management of primary care patients with suspected deep vein thrombosis: use of a therapeutic dose of low-molecular-weight heparin to avoid urgent ultrasonographic evaluation. *Journal of thrombosis and haemostasis : JTH* 2006;4:1037-41.
22. Janes S, Ashford N. Use of a simplified clinical scoring system and D-dimer testing can reduce the requirement for radiology in the exclusion of deep vein thrombosis by over 20%. *Br J Haematol* 2001;112:1079-82.
23. Kahn SR, Joseph L, Grover SA, Leclerc JR. A randomized management study of impedance plethysmography vs. contrast venography in patients with a first episode of clinically suspected deep vein thrombosis. *Thromb Res* 2001;102:15-24.
24. Kearon C, Ginsberg JS, Douketis J, et al. Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing. *Annals of internal medicine* 2001;135:108-11.
25. Kearon C, Ginsberg JS, Douketis J, et al. A randomized trial of diagnostic strategies after normal proximal vein ultrasonography for suspected deep venous thrombosis: D-dimer testing compared with repeated ultrasonography. *Annals of internal medicine* 2005;142:490-6.
26. Kraaijenhagen RA, Piovella F, Bernardi E, et al. Simplification of the diagnostic management of suspected deep vein thrombosis. *Archives of internal medicine* 2002;162:907-11.
27. Le GG, Kercret G, Ben YK, et al. Diagnostic value of single complete compression ultrasonography in pregnant and postpartum women with suspected deep vein thrombosis: prospective study. *BMJ (Clinical research ed)* 2012;344:e2635.
28. Legnani C, Cini M, Scarvelis D, Toulon P, Wu JR, Palareti G. Multicenter evaluation of a new quantitative highly sensitive D-dimer assay, the Hemosil D-dimer HS 500, in patients with clinically suspected venous thromboembolism. *Thromb Res* 2010;125:398-401.
29. Linkins LA, Bates SM, Lang E, et al. Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial. *Annals of internal medicine* 2013;158:93-100.
30. Noren A, Ottosson E, Rosfors S. Is it safe to withhold anticoagulation based on a single negative color duplex examination in patients with suspected deep venous thrombosis? A prospective 3-month follow-up study. *Angiology* 2002;53:521-7.



31. Penalzoza A, Laureys M, Wautrecht JC, Lheureux PH, Motte S. Accuracy and safety of pretest probability assessment of deep vein thrombosis by physicians in training using the explicit Wells clinical model [9]. *Journal of Thrombosis and Haemostasis* 2006;4:278-81.
32. Perrier A, Desmarais S, Miron MJ, et al. Non-invasive diagnosis of venous thromboembolism in outpatients. *Lancet* 1999;353:190-5.
33. Prandoni P, Lensing AW, Bernardi E, Villalta S, Bagatella P, Girolami A. The diagnostic value of compression ultrasonography in patients with suspected recurrent deep vein thrombosis. *Thrombosis and haemostasis* 2002;88:402-6.
34. Prandoni P, Tormene D, Dalla VF, Concolato A, Pesavento R. D-dimer as an adjunct to compression ultrasonography in patients with suspected recurrent deep vein thrombosis [6]. *Journal of Thrombosis and Haemostasis* 2007;5:1076-7.
35. Robinson BJ, Kesteven PJ, Elliott ST. The role of strain gauge plethysmography in the assessment of patients with suspected deep vein thrombosis. *Br J Haematol* 2002;118:600-3.
36. Ruiz-Gimenez N, Frieria A, Artieda P, et al. Rapid D-dimer test combined a clinical model for deep vein thrombosis. Validation with ultrasonography and clinical follow-up in 383 patients. *Thrombosis and haemostasis* 2004;91:1237-46.
37. Schellong SM, Schwarz T, Halbritter K, et al. Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosis. *Thrombosis and haemostasis* 2003;89:228-34.
38. Schouten HJ, Koek HL, Oudega R, van Delden JJ, Moons KG, Geersing GJ. Validation of the Oudega diagnostic decision rule for diagnosing deep vein thrombosis in frail older out-of-hospital patients. *Fam Pract* 2015;32:120-5.
39. Schutgens RE, Ackermack P, Haas FJ, et al. Combination of a normal D-dimer concentration and a non-high pretest clinical probability score is a safe strategy to exclude deep venous thrombosis. *Circulation* 2003;107:593-7.
40. Siragusa S, Anastasio R, Porta C, et al. Deferment of objective assessment of deep vein thrombosis and pulmonary embolism without increased risk of thrombosis: a practical approach based on the pretest clinical model, D-dimer testing, and the use of low-molecular-weight heparins. *Archives of internal medicine* 2004;164:2477-82.
41. Sluzewski M, Koopman MMW, Schuur KH, Van Vroonhoven TJMV, Ruijs JHJ. Influence of negative ultrasound findings on the management of in- and outpatients with suspected deep-vein thrombosis. *European Journal of Radiology* 1991;13:174-7.
42. Stevens SM, Elliott CG, Chan KJ, Egger MJ, Ahmed KM. Withholding anticoagulation after a negative result on duplex ultrasonography for suspected symptomatic deep venous thrombosis. *Annals of internal medicine* 2004;140:985-91.
43. Stevens SM, Woller SC, Graves KK, et al. Withholding anticoagulation following a single negative whole-leg ultrasound in patients at high pretest probability for deep vein thrombosis. *Clin Appl Thromb Hemost* 2013;19:79-85.
44. Subramaniam RM, Heath R, Chou T, Cox K, Davis G, Swarbrick M. Deep venous thrombosis: withholding anticoagulation therapy after negative complete lower limb US findings. *Radiology* 2005;237:348-52.
45. Subramaniam RM, Heath R, Cox K, Chou T, Stewart J, Sleight J. Does an immunochromatographic D-dimer exclude acute lower limb deep venous thrombosis? *Emerg Med Australas* 2006;18:457-63.

46. ten Wolde M, Kraaijenhagen RA, Prins MH, Buller HR. The clinical usefulness of D-dimer testing in cancer patients with suspected deep venous thrombosis. *Archives of internal medicine* 2002;162:1880-4.
47. Tick LW, Ton E, van VT, et al. Practical diagnostic management of patients with clinically suspected deep vein thrombosis by clinical probability test, compression ultrasonography, and D-dimer test. *Am J Med* 2002;113:630-5.
48. Van der Hulle T, Tan M, den Exter PL, et al. Selective D-dimer testing for the diagnosis of acute deep vein thrombosis: A validation study. *Journal of Thrombosis and Haemostasis* 2013;11:2184-6.
49. Wells PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. *Lancet* 1997;350:1795-8.
50. Wells PS, Anderson DR, Bormanis J, et al. Application of a diagnostic clinical model for the management of hospitalized patients with suspected deep-vein thrombosis. *Thrombosis and haemostasis* 1999;81:493-7.
51. Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. *N Engl J Med* 2003;349:1227-35.



